Clinical Trials
3 trialsNCT04674813 2026-02-09
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, a Subsidiary of Celgene
Phase 1 Completed
NCT05182073 2025-12-12
FT576 in Subjects With Multiple Myeloma
Fate Therapeutics
Phase 1 Completed
NCT02315157 2025-10-15
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
Thomas Jefferson University
Phase 1 Withdrawn